Literature DB >> 7774047

Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor.

I H Choi1, T Y Ha, D G Lee, J S Park, J H Lee, Y M Park, H K Lee.   

Abstract

The possible occurrence of DIC in active systemic anaphylaxis was investigated in mice. Induction of active systemic anaphylaxis resulted in the development of DIC symptoms such as thrombocytopenia, prolongation of prothrombin time, hypofibrinogaemia, and elevated level of fibrinogen/fibrin degradation products. In addition, in histological examinations, massive congestion and cellular infiltration in pulmonary interstitia, and considerable haemorrhage in renal medullae were observed. All these changes were nearly completely prevented by pretreatment with platelet-activating factor (PAF) antagonist (BN 50739). Moreover, the same haematological and morphological changes were produced by a bolus injection of PAF. These data strongly suggest that DIC occurs in active systemic anaphylaxis and PAF plays a pivotal role in the development of DIC in anaphylaxis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7774047      PMCID： PMC1534480          DOI： 10.1111/j.1365-2249.1995.tb03711.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  22 in total

1.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.

Authors:  Y Imura; Z Terashita; K Nishikawa
Journal:  Life Sci       Date:  1986-07-14       Impact factor: 5.037

Review 3.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

4.  Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans.

Authors:  K A Bauer; H ten Cate; S Barzegar; D R Spriggs; M L Sherman; R D Rosenberg
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

5.  Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma.

Authors:  F H Valone; L B Epstein
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

6.  Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021.

Authors:  B Vilain; V Lagente; C Touvay; S Desquand; J Randon; J Lefort; P Braquet; B B Vargaftig
Journal:  Pharmacol Res Commun       Date:  1986-08

7.  Production of active and passive anaphylactic shock in the WBB6F1 mouse, a mast cell-deficient strain.

Authors:  A Arimura; M Nagata; A Watanabe; K Nakamura; M Takeuchi; M Harada
Journal:  Experientia       Date:  1990-07-15

8.  Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.

Authors:  J M Herbert; L Lespy; J P Maffrand
Journal:  Eur J Pharmacol       Date:  1991-12-03       Impact factor: 4.432

9.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.

Authors:  G Camussi; F Bussolino; G Salvidio; C Baglioni
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases.

Authors:  G Camussi; C Tetta; F Bussolino; C Baglioni
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307
View more
  7 in total

1.  Selective involvement of reactive oxygen intermediates in platelet-activating factor-mediated activation of NF-kappaB.

Authors:  J H Choi; W J Chung; S J Han; H B Lee; I W Choi; H K Lee; K Y Jang; D G Lee; S S Han; K H Park; S Y IM
Journal:  Inflammation       Date:  2000-10       Impact factor: 4.092

2.  A protective role of platelet-activating factor in murine candidiasis.

Authors:  S Y Im; J H Choi; H M Ko; S J Han; S B Chun; H K Lee; T Y Ha
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

Review 3.  Allergy and the cardiovascular system.

Authors:  M Triggiani; V Patella; R I Staiano; F Granata; G Marone
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 4.  The Mast Cell, Contact, and Coagulation System Connection in Anaphylaxis.

Authors:  Mar Guilarte; Anna Sala-Cunill; Olga Luengo; Moisés Labrador-Horrillo; Victoria Cardona
Journal:  Front Immunol       Date:  2017-07-26       Impact factor: 7.561

5.  Allergy, inflammation, hepatopathy and coagulation biomarkers in dogs with suspected anaphylaxis due to insect envenomation.

Authors:  Kate Turner; Corrin Boyd; Gabriele Rossi; Claire R Sharp; Melissa A Claus; Abbie Francis; Lisa Smart
Journal:  Front Vet Sci       Date:  2022-08-08

6.  Disseminated Intravascular Coagulation, Hemoperitoneum, and Reversible Ischemic Neurological Deficit Complicating Anaphylaxis to Prophylactic Antibiotics during Cesarean Delivery: A Case Report and Review of Literature.

Authors:  Mostafa A Borahay; Hassan M Harirah; Gayle Olson; Gokhan S Kilic; Sinem Karipcin; Gary D V Hankins
Journal:  AJP Rep       Date:  2011-01-24

7.  Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice.

Authors:  I H Choi; Y M Shin; J S Park; M S Lee; E H Han; O H Chai; S Y Im; T Y Ha; H K Lee
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.